2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1942

Presentation and Clinical Features of ANCA-Associated Vasculitis in US African Americans: Experience from a Single Center
Abstract Number: 1949

Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides
Abstract Number: 935

Pretreatment Plasma IL-6 Levels Are Responsible for Bone Erosion Progression on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis
Abstract Number: 1785

Prevalence and Associated Factors of Low Bone Mass in Adults with Systemic Lupus Erythmatosus
Abstract Number: 1508

Prevalence and Clinical Characteristics of Rheumatoid Arthritis in Sickle Cell Patients: A Cross-Sectional Analysis
Abstract Number: 1537

Prevalence and Impact of Inflammatory Multimorbid Conditions on Trajectories of Disease Activity in the First Year of Follow-up in a Multi-Center Era Cohort
Abstract Number: 719

Prevalence and Incidence of Comorbidities in Patients with Ankylosing Spondylitis Versus General Population
Abstract Number: 1813

Prevalence and Incidence of Systemic Lupus Erythematosus in Tucuman -Argentina
Abstract Number: 3234

Prevalence and Metric of Depression and Anxiety in Lupus: A Systematic Review and Meta-Analys
Abstract Number: 2655

Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs
Abstract Number: 2185

Prevalence and Trends in Prescribed Opioid Use Among US Adults with Arthritis, 2008-2013, Medical Expenditure Panel Survey
Abstract Number: 2687

Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive ANTI-RO and ANTI-La Antibodies
Abstract Number: 2584

Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs
Abstract Number: 2843

Prevalence of Anti-DFS70 Antibodies in Patients with and without Systemic Autoimmune Rheumatic Diseases
Abstract Number: 1876

Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].